Swiss medical device developer CorFlow Therapeutics said today it closed a $2.7 million (CHF 2.6 million) Seed+ round of financing to support a first-in-man trial of its platform designed to diagnose and treat microvascular obstructions.
The round was led by private medical device investors and brings the total seed funding raised by the company up to $5.1 million (CHF 5 million). Also joining the round were CoreValve and CardiAQ founders Jacques Séguin and Arshad Quadri and CoreValve and CardiaQ tech developer Dr. Jean-Claude Laborde, the company said.
“The CorFlow Controlled Flow Infusion technology is a compelling and powerful new approach to diagnose and potentially treat microvascular obstruction after a heart attack. We are proud to support a high quality European medical device company like CorFlow and look forward to follow and support the company as investors,” Séguin, Quadri and Laborde said in a joint statement.
Proceeds from the round will support an 80-patient trial of the company’s MVO with CorFlow Controlled Flow Infusion technologies in Europe.
The trial will explore the diagnosis of microvascular obstruction in up to 40 acute coronary patients as well as potential therapy, comparing outcomes between the company’s tech and current standard of care.
“I’m very grateful for the continued and substantial support that we are receiving from our private investors. The fundament for the Seed+ financing is the data coming out of CorFlow’s nonclinical trials and our solid milestone achievements. We are pleased that leading professionals like Jacques, Jean-Claude and Q share our view on the nonclinical data. These data are very exciting and open a completely new window to diagnose and potentially treat microvascular obstruction,” CorFlow CEO & co-founder Jon Hoem said in a press release.